Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis.

Area of Science:

• Neurology
• Immunology
• Clinical Therapeutics

Background:

• Secondary progressive multiple sclerosis (SPMS) is characterized by frequent relapses and rapid disability progression.
• Current treatments often have limited efficacy in halting disease activity in highly active SPMS.
• Investigating novel therapeutic strategies is crucial for managing advanced MS.

Purpose of the Study:

• To evaluate the safety and efficacy of pulse cyclophosphamide (CTX) therapy.
• To assess clinical and MRI outcomes in patients with very active SPMS.
• To determine if CTX can halt disease progression in rapidly deteriorating MS.

Main Methods:

• Sixteen patients with active SPMS received intravenous pulse cyclophosphamide (CTX) for 24 months.
• Treatment involved high-dose CTX every four weeks for the first year, then every eight weeks.
• Clinical assessments (EDSS, relapse rates) and MRI scans were performed at baseline, 12, and 24 months; a control group was included.

Main Results:

• CTX therapy was safe and well-tolerated, with no severe adverse events.
• Expanded Disability Status Scale (EDSS) significantly decreased from 5.6 to 4.1 (p<0.001).
• Relapse rate dropped significantly from 3.0/year to 0.25/year (p<0.0001), with no relapses in the second year; no increase in T2 lesion load observed.

Conclusions:

• Pulse cyclophosphamide (CTX) therapy is a safe and effective treatment for highly active secondary progressive multiple sclerosis.
• CTX significantly reduces relapse rates and disability progression.
• The therapy halts disease activity and MRI-detected progression in rapidly evolving SPMS.